Compare Bilibili Inc (BILI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Bilibili Inc trades at $17.75 (market cap $7.65B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 17.5× Bilibili Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | VRTX | |
|---|---|---|
Market Cap | $7.65B | $134.25B |
Sector | Media | Health |
52-Week High | $35.92 | $529.65 |
52-Week Low | $15.96 | $376.62 |
Enterprise Value | $5.49B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $18.74, up 0.48% with neutral technical signals. The company reported strong Q1 2026 earnings of $0.19 per share, beating estimates, and maintains solid profitability with a 4.58% net margin. Recent news highlights a new $300 million share repurchase program and upcoming Q2 2026 results on August 27, 2026. Technical indicators show mixed signals with RSI neutral but moving averages bullish.
Bilibili presents a compelling investment case with consistent earnings beats and strong analyst support (83% buy ratings). However, risks include competitive pressures in China's video platform market and reliance on advertising revenue growth. The upcoming Q2 earnings report will be crucial for validating the company's monetization strategy and user engagement metrics.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
